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Background: A phase I–II multicenter trial was conducted to define the maximum tolerated dose (MTD)
according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of
response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continu-
ous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer.
Patients and methods: Patients with measurable unresectable and/or metastatic gastric carcinoma, World
Health Organization performance status ≤1, normal hematological and renal functions, adequate hepatic func-
tion and not pretreated for advanced disease by chemotherapy, received up to eight cycles of a combination of
docetaxel on day 1, cisplatin on day 1 and 5-FU p.i.v. on days 1–14 (TCF) every 3 weeks, which was escalated
up to the MTD, defined by the occurrence of dose-limiting toxicity in two patients in one dose level.
Results: Fifty-two patients were accrued and treated (43 in the phase I part of the trial and nine additional at the
recommended dose level). A median of five cycles/patient was given. The recommended dose of TCF was
docetaxel 85 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1 and 5-FU p.i.v. 300 mg/m2/day on days 1–14. Grade
≥3 toxicities were neutropenia 79%, alopecia 46%, fatigue 23%, mucositis 10%, diarrhea 19%, nausea/vomit-
ing 13%, neurological 4% and palmar-plantar 2%. Ten non-fatal febrile neutropenia episodes were recorded in
eight patients. There were no treatment-related deaths. Among 41 patients with measurable disease (79%), we
observed one complete and 20 partial responses for an overall intent-to-treat response rate of 51% (95% confi-
dence interval 35–67%). Five patients (20%) had stable disease for ≥12 weeks (four cycles). The median overall
survival was 9.3 months.
Conclusions: 5-FU p.i.v. at 300 mg/m2/day for 2 weeks out of three could be safely added to the docetaxel–
cisplatin (TC) combination, but the dose of docetaxel had to be reduced to 75 mg/m2 in a subsequent phase II
trial. This drug regimen seems to be very active in advanced gastric cancer. Comparison with both TC and ECF
in a randomized SAKK trial is ongoing.
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Introduction
Despite a decline in its incidence, gastric carcinoma remains one
of the 10 leading causes of death by neoplasia in Western countries
[1]. Surgery remains the treatment of choice for cure. Unfor-
tunately, more than half of patients present with stage III or IV
disease, which precludes resection. Up to relatively recently,
chemotherapy has generally been considered as ineffective in this
disease, and was used as a palliative measure for advanced cases
only.
Over the last 6–7 years promising new drug regimens have been
proposed in the treatment of this disease. Epirubicin–cisplatin–
5-fluorouracil (5-FU) in continuous infusion (ECF) was devel-
oped in the UK. Compared with 5-FU–adriamycin–methotrexate
(FAMTX) in a phase III randomized trial, ECF yielded a superior
response rate (45% versus 21%) and superior median time to pro-
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gression (7.4 versus 3.4 months), with better overall survival.
These data led the investigators to propose ECF as standard prac-
tice [2]. An intensive weekly chemotherapy called PELF (cispla-
tin, epirubicin, 5-FU and leucovorin) was studied in Italy and was
reported to yield a 62% response rate in a large phase II trial
enrolling 105 patients [3]. However, toxicity was substantial,
requiring regular use of colony stimulating factors.
Several promising new drugs belonging to the taxane and cam-
pothecine groups now have been studied and introduced in the
systemic therapy of this disease [4]. Among them, docetaxel
(60–100 mg/m2) as a single agent was shown in three separate
phase II studies to yield a response rate of 17–24% [5–7]. These
data prompted us to investigate docetaxel in combination with
cisplatin (TC) in a phase II trial in gastric carcinoma [8]. With an
objective response rate of 56% in 48 treated patients, it was con-
cluded that TC was active in advanced gastric cancer. Despite its
relatively high hematotoxicity, this regimen was well tolerated
and could be recycled as originally planned in 78% of the cases.
Based on these results we felt TC was promising enough to
serve as the core for a new combination involving a third drug.
Because of the relatively high hematotoxicity induced by
docetaxel, it was felt that only a moderately myelotoxic drug
could be added to this regimen without requiring an important
dose reduction of docetaxel and cisplatin. 5-FU given in pro-
tracted continuous infusion may be an interesting option since it is
known to induce very little myelotoxicity, if any. Furthermore, the
positive results obtained with the ECF regimen in advanced gas-
tric cancer suggest that protracted continuous infusion might be
the most efficient way of administering 5-FU in this disease [9,
10].
A phase I trial exploring the combination of docetaxel and 5-FU
showed that docetaxel at 85 mg/m2 with 5-FU given in continuous
infusion over 5 days at 750 mg/m2/day was tolerable without any
major mucosal toxicity or any substantial increase in docetaxel-
induced myelotoxicity [11]. This indicates that the addition of
5-FU in protracted continuous infusion to docetaxel and cisplatin
may be reasonable and feasible.
We report the results of a phase I–II trial investigating the maxi-
mum tolerated dose (MTD), tolerability and, as secondary end
point, the efficacy of the combination of docetaxel, cisplatin and
5-FU in protracted continuous infusion (TCF) in inoperable
advanced gastric cancer.
Patients and methods
Patients with metastatic or locally advanced adenocarcinoma of the stomach
not previously treated palliatively by systemic therapy and not amenable to
curative resection were enrolled in this trial. The patients were required to have
a World Health Organization (WHO) performance status ≤1, normal blood
counts, creatinine clearance ≥60 ml/min, adequate liver function tests
[bilirubin <1× upper limit of normal (ULN), AST/ALT <2.5× ULN], no his-
tory of anaphylaxis and no peripheral neuropathy of any origin greater than
grade 1. Patients with bidimensionally measurable or simply evaluable disease
were eligible (elevated tumor markers or unidimensionally measurable dis-
ease).
The treatment consisted of docetaxel on day 1 in a 1 h intravenous (i.v.)
infusion followed by cisplatin on day 1 in a 4 h i.v. infusion and 5-FU in pro-
tracted continuous infusion (p.i.v.) from day 1 to day 14, according to the dose
levels described in Table 1. Day 1 of each treatment cycle was given on an
in-patient basis in order to ensure correct hyperhydration for cisplatin adminis-
tration. Patients were to be treated at the same dose level in groups of three. If
no dose-limiting toxicity (DLT), defined as grade 4 hematological toxicity
with fever (single oral temperature >38.5°C, or three elevations to 38°C during
a 24-h period) and/or grade 3 toxicity of any other kind apart from alopecia,
occurred, the next three patients were treated at the next higher dose level. If
one DLT occurred in cycle one, three additional patients had to be treated at the
same dose level. If two or more DLTs occurred at a given dose level, the MTD
would be considered to be reached and the dose escalation had to be stopped.
The dose just below would be considered to be the recommended dose for
future evaluation in phase II trials. All patients received a standard supportive
regimen consisting of hyperhydration (3 l of normal saline or 5% dextrose/
24 h) during each course of treatment and dexamethasone (Fortecortine®) 8 mg
orally administered 12 and 6 h before docetaxel infusion and 8 mg twice daily
for an additional 4 days. 5-HT3 inhibitors were used for emesis prophylaxis.
The use of hematological growth factors was not permitted during the first
cycle of treatment, but was allowed thereafter if needed.
After completion of eight cycles of treatment or discontinuation of chemo-
therapy, disease status was re-evaluated every 3 months. Toxicity was
assessed according to WHO grading for each cycle.
The next cycle of treatment could be postponed for no more than 2 weeks to
allow the resolution of toxicities. Patients were to be taken off trial treatment in
case of delays longer than 2 weeks. A 15 mg dose reduction of docetaxel was
mandatory in case of prolonged grade 4 neutropenia (>7 days), grade 4 thrombo-
cytopenia, grade ≥2 liver toxicity and grade 3 cutaneous toxicity. A further
25% dose reduction was foreseen in the event that the same type/grade toxicity
was observed in subsequent cycles. If grade 2 neurotoxicity was recorded the
dose of docetaxel was to be reduced by 15 mg, along with a 15 mg reduction in
cisplatin dose. Cisplatin was reduced when the creatinine clearance dropped
below 60 ml/min, and discontinued if it decreased below 40 ml/min. 5-FU was
due to be reduced by 50 mg/m2/day in case of grade 2 diarrhea, mucositis or
palmar-plantar syndrome and by 75 mg/m2/day in case of grade 3 palmar-
plantar syndrome and by 100 mg/m2/day at the occurrence of grade 3 mucositis
or diarrhea. Trial treatment was stopped in case of persistent grade 3 liver tox-
icity, grade ≥3 neuropathy, grade 4 cutaneous toxicity, grade 3 anaphylactoid
reaction and if a toxicity recurred despite dose reductions.
The primary objective of the trial was to define the MTD of the regimen
under investigation, and all evaluations were purely descriptive. Response, a
secondary end point, was assessed according to WHO criteria at the end of
every alternate cycle of treatment. Survival, another secondary end point, was
determined using the Kaplan–Meier method. The trial was approved by the
Table 1. Dose escalation scheme
p.i.v., protracted continuous infusion; 5-FU, 5-fluorouracil.
Level Cisplatin, 
mg/m2
Docetaxel, 
mg/m2
5-FU p.i.v. 2 of 3 weeks, 
mg/m2/day
1 60 70 200
2 60 85 200
3 75 85 200
4 75 85 225
5 75 85 250
6 75 85 275
7 75 85 300
8 75 85 350
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ethics review boards of all participating institutions. All patients gave written
informed consent.
Results
Fifty-two patients were enrolled in the trial. One further patient
was recruited, but refused participation prior to any trial treatment,
and was excluded from all analyses. Patient characteristics are
summarized in Table 2. There were 37 males and 15 females,
whose performance status was 0 (50%), 1 (44%) and 2 (6%).
Thirty-seven per cent of the patients had previously undergone a
surgical resection of their primary tumor (total or subtotal gastrec-
tomy), and three (6%) had received neo-adjuvant or adjuvant
chemotherapy. At the time of inclusion into the trial, patients had
lost a median of 2 kg of weight over the last 3 months. All 52
patients were evaluable for toxicity. Forty-one patients (79%) had
bidimensionally measurable disease, whereas 11 had evaluable
disease only.
Forty-three patients were accrued during the dose-finding part
of the trial and nine additional patients were enrolled to ascertain
the safety of the recommended dose level. Table 3 presents the
accrual and tolerance per dose level. Twelve patients had to be
enrolled in dose level 1 before escalation. This was due to the
occurrence in the first six patients enrolled of one episode of
febrile neutropenia (FN) and of one occurrence of borderline
grade 3 diarrhea. After discussion with the concerned investi-
gators, this latter toxicity was considered to be too ambiguous to
consider it as a DLT and consider this dose level as MTD. There-
fore, an amendment was issued and submitted to all ethical comit-
tees to allow the accrual of six additional patients at this dose level
to resolve these ambiguities and better assess the toxicity. Again,
DLTs were observed in two patients, one FN and one with grade 3
self-resolving abdominal pain of uncertain origin. The relation-
ship to the treatment of the latter toxicity remained uncertain. It
was therefore decided to start dose escalation. The original proto-
col was designed with five dose levels. Three additional dose
levels incrementing the 5-FU dosage had to be subsequently
added, and the MTD was reached at dose level 8 (two DLTs in
four patients). Dose level 7 was therefore the recommended
regimen with docetaxel 85 mg/m2 on day 1, cisplatin 75 mg/ m2 on
day 1 and 5-FU 300 mg/ m2/day on days 1–14.
The toxicity analysis is based on 52 patients and 255 cycles of
treatment. Overall this regimen was well tolerated and a median of
five cycles per patient could be administered. Six patients com-
pleted the planned eight cycles of treatment. Twenty-one patients
stopped therapy beforehand due to progressive disease, 20
stopped for personal reasons (nine patients), because of toxicity
(seven patients) or by physician’s decision (four patients), and
three were referred to surgery for gastrectomy after response to
treatment. Two patients died early from disease. In 55 cycles out
of 255 (22%) the treatment was delayed by more than 3 days.
Table 4 summarizes grade 3–4 hematological toxicities per
patient and per cycle. Despite the relatively frequent occurrence of
Table 2. Patient characteristics
WHO, World Health Organization.
Characteristic n (%)
No. of patients 52
Age, years [median (range)] 58 (30–70)
Sex (male/female) 37/15 (71/29)
WHO performance status (0/1/2) 26/23/3 (50/44/6)
Appetite, good/fair/none 33/15/4 (63/29/8)
Weight change in last 3 months (kg)
Median (range) –2 (–15 to +4)
Previous surgery 19 (37)
Previous adjuvant chemotherapy 3 (6)
No. of affected disease sites per patient
Median (range) 3 (1–5)
Patients with locally advanced disease only 7
No. of disease sites per patient
1 8
2 15
3 17
≥4 12
Disease sites (measurable and not measurable)
Lymph nodes 35
Stomach 36
Liver 26
Peritoneum 20
Lung 8
Bone 4
Others 11
Bidimensionally measurable disease 41 (79)
Table 3. Dose-limiting toxicities (DLTs) according to dose level
Dose 
levels
No. of 
patients
DLTs (cycle 1) Median cycles/
patient
1 12 Febrile neutropenia (n = 2) 6
Grade 3 abdominal pain (n = 1)
Grade 3 diarrhea (n = 1)
2 6 Grade 3 diarrhea and nausea (n = 1) 4
3 6 Febrile neutropenia (n = 1) 6
4 3 None 8
5 6 Febrile neutropenia (n = 1) 2.5
6 3 None 6
7 3 None 6
8 4 Febrile neutropenia (n = 1) 4.5
Grade 3 mucositis and 
diarrhea (n = 1)
≥2 DLTs resulted in stop of 
dose escalation
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grade 3/4 granulocytopenia, only 10 episodes of non-fatal FN
were seen in eight patients (15% of the patients, 4% of the treat-
ment cycles). Other main toxicities are reported per patient in
Table 5 and per cycle in Table 6. Four patients presented catheter-
related complications. One patient presented with an infection of
the catheter which had to be removed. The three other patients pre-
sented with axillary venous thrombosis which necessitated anti-
coagulation with coumadine. One patient died from progressive
disease 21 days after having received treatment in cycle 3.
Another patient died 31 days after his last dose of chemotherapy
with evidence of peritonitis secondary to intestinal perforation of
unclear origin. There were no other deaths during the treatment
period that could be considered to be related to the trial treatment.
Other recorded grade 3/4 toxicities were two episodes of transit-
ory loss of consciousness in one patient during cycles 3 and 6, five
episodes of self-resolving abdominal pain and epigastralgia of
uncertain origin, one episode of subileus, one occurrence of grade
3 hypertonia, and one aggravation of Alzheimer’s disease after the
first cycle of treatment.
At the end of the dose-finding part of the study, nine additional
patients were enrolled to ascertain the safety of the recommended
dose level. A separate analysis of the data from the 12 patients
treated at the recommended dose level 7 (three patients accrued
during the dose-finding part plus nine additional patients) was
performed. The toxicity and tolerance were similar to what was
observed in the whole trial. Notably, rates of grade 3/4 maximal
hematological toxicities were 25%/58% in the 12 patients on dose
level 7, and 33%/52% in the whole patient population, while grade
3/4 maximum non-hematological toxicities were 33%/8% and
28%/6%, respectively.
Although this was not an inclusion requirement, 41 patients
(79%) had bidimensionally measurable disease, allowing us to
make an accurate response rate assessment (Table 7). One com-
plete response (CR) and 23 partial responses (PR), including three
unconfirmed, were recorded, for a response rate of 59% [24 of 41
patients; 95% confidence interval (CI) 42–74%]. Five patients had
stable disease during at least four cycles of treatment, 10 patients
progressed immediately during therapy, and two discontinued
treatment after one cycle only due to excessive toxicity. Among
the 11 patients with evaluable only disease, six were considered as
responding to the treatment. One patient had his primary tumor
resected after six cycles of treatment. The median overall survival
was 9.3 months (Figure 1) with a 95% CI of 7.7–10.8 months.
Forty-seven patients had died at the time of the present evaluation.
Discussion
This trial shows that 5-FU p.i.v. at 300 mg/m2/day for 2 weeks out
of 3 can be added to TC without any alteration of the dose levels of
docetaxel and cisplatin. It also confirms the results of our earlier
phase II trial with TC regarding the feasibility, the relative good
Table 4. Grade 3/4 hematoxicity per cycle and per patient
Hematological toxicity % of 255 cycles % of 52 patients
Grade 3 Grade 4 Grade 3 Grade 4
Leukocytopenia 19 2 42 8
Granulocytopenia 28 22 27 52
Thrombocytopenia 0 0 0 0
Table 5. Non-hematological toxicity as percentage of 52 patients
aGrades: 1, mild; 2, moderate; 3, severe.
Toxicity Grade
1 2 3 4
Nausea/vomiting (%) 33 31 12 2
Diarrhea (%) 33 33 17 2
Mucositis (%) 40 27 8 2
Fatigue (%) 29 42 21 2
Plantar-palmar syndrome (%) 21 8 2 –
Alopecia (%) 10 38 44 2
Neurological (%) 33 12 4 –
Fluid retentiona (%) 27 2 – –
Hypersensitivity reactiona (%) 23 2 2 –
Table 6. Non-hematological toxicity as percentage of 255 cycles of 
treatment
aGrades: 1, mild; 2, moderate; 3, severe.
Toxicity Grade
1 2 3 4
Nausea/vomiting (%) 29 13 3 0.4
Diarrhea (%) 21 10 4 0.4
Mucositis (%) 18 10 3 0.4
Fatigue (%) 42 20 6 0.4
Plantar-palmar syndrome (%) 6 3 0.4 –
Alopecia (%) 14 33 31 –
Neurological (%) 18 5 1 –
Fluid retentiona (%) 21 0.4 – –
Hypersensitivity reactiona (%) 20 0.4 0.4 –
Table 7. Tumor response (patients with 
bidimensionally measurable disease)
CR, complete response; PD, progressive disease; 
PR, partial response; SD, stable disease.
Overall best response No. of patients 
(41) (%)
CR 1 (2)
PR 20 (49)
PR not confirmed 3 (7)
SD (for ≥4 cycles) 5 (12)
PD 10 (25)
Not evaluable 2 (5)
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tolerability and the activity of docetaxel–cisplatin based combin-
ation in advanced gastric carcinoma [8].
As originally expected, the addition of 5-FU p.i.v. to TC did not
increase the hematotoxicity compared with what we observed
previously with TC alone [8]. Eight of the 52 enrolled patients in
this trial presented 10 episodes of non-fatal FN, while we
observed nine such episodes in our previous TC trial enrolling 48
patients. With the addition of 5-FU p.i.v., the main changes in the
non-hematological toxicity were observed in the occurrence of
grade 1/2 diarrhea and mucositis, and in the appearance of plantar-
palmar syndrome. All three toxicities are known to be associated
with 5-FU. The incidence per cycle of grade 1/2 diarrhea
increased from 5%/5% with TC to 21%/10% with TCF, while the
occurrence of grade 3 diarrhea rose from 2% to 4%, and grade 4
episodes remained the exception. Similarly, the occurrence of
grade 1/2 mucositis went from 13%/4% with TC to 18%/10%
with TCF, while grade 3 mucositis went up from 2% to 3% and
grade 4 was rarely seen. Plantar-palmar syndrome of some degree
occurred in 31% of the patients but was mainly of benign inten-
sity. Only four patients had their 5-FU reduced by 25% because of
the occurrence of grade 2/3 plantar-palmar syndrome, and two of
them encountered a cycle delay. An unexplained increase in grade 1
fluid retention and hypersensitivity reactions most probably
related to docetaxel were also observed. It is interesting to note
that, despite these changes of toxicity profile, the median number
of cycles of TCF administered per patient was five, as in our
previous trial with TC. This suggests that the increase of toxicity
did not affect significantly the overall tolerance of and the compli-
ance with the treatment.
The examination of the DLT occurrences during the dose-find-
ing part of the study reported in Table 3 confirms that the hemato-
toxicity leading to episodes of FN remains the main DLT of this
docetaxel-based regimen. FN seems to have occurred in an unpre-
dictable fashion, independently of the dose level considered.
Actually, no FN episode occurred in the nine additional patients
accrued at level 7 in the confirmatory part of the trial. This might
also be the result of an increase in the use of hematological growth
factors later in the trial, which were prohibited during the first
cycle of the dose-finding part of the study.
Despite the acceptable toxicity results obtained formerly in 48
patients treated with TC and in 40 patients treated with TCF here,
both given with docetaxel at 85 mg/m2, further experience
acquired with TC and TCF in our current randomized phase II trial
with TC versus TCF versus ECF showed an unexpected higher
occurrence of FN episodes with both docetaxel-based regimens
(TC and TCF) in the first 30 patients enrolled (SAKK Trials
Office, personal communication) [8]. The protocol was then
amended and the dose of docetaxel reduced from 85 mg/m2 to
75 mg/m2 on day 1 in both TC and TCF, leading to a reduction of
FN events. This dosage is also frequently recommended and used
by others in combination with cisplatin ± 5-FU in metastatic
gastric cancer as well as in other tumors [12–15]. We would there-
fore recommend using docetaxel at 75 mg/m2 on day 1 instead of
85 mg/m2 in both TC and TCF regimens.
Since nearly 80% of the patients had measurable disease, an
efficacy assessment could be performed in this patient population.
The 51% response rate (CRs plus confirmed PRs) and the median
overall survival of 9.3 months are in line with the results already
published with TC, and are well within the same range reported by
others in metastatic gastric cancer [8, 12, 14]. A formal compar-
ison between TC and TCF is needed to evaluate if the addition of
5-FU to TC translates into an advantage in efficacy, making the
risk of moderate additional toxicity linked to it worthwhile. Our
randomized phase II trial with TC versus TCF versus ECF is
currently ongoing.
In conclusion, the addition of 5-FU 300 mg/m2 in continuous
infusion for 2 weeks out of 3 to docetaxel 75 mg/m2 and cisplatin
75 mg/m2 on day 1 is feasible with only a moderate increase of
non-hematological toxicity, which does not seem to affect the
overall patient tolerance. This drug regimen seems to be very
active in advanced gastric carcinoma, and a further evaluation of
efficacy and toxicity is currently underway in a randomized phase
II trial of TC versus TCF versus ECF.
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